Ilia I. Ouspenski

Array ( [id] => 12425022 [patent_doc_number] => 09974845 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-05-22 [patent_title] => Combination of vaccination and inhibition of the PD-1 pathway [patent_app_type] => utility [patent_app_number] => 14/769720 [patent_app_country] => US [patent_app_date] => 2014-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 34130 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14769720 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11767922 [patent_doc_number] => 09376498 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-06-28 [patent_title] => 'Anti-CD26 antibodies and uses thereof' [patent_app_type] => utility [patent_app_number] => 14/184241 [patent_app_country] => US [patent_app_date] => 2014-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 19 [patent_no_of_words] => 34255 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14184241 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10554811 [patent_doc_number] => 09279008 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-03-08 [patent_title] => 'Isolated B7-H4 specific compositions and methods of use thereof' [patent_app_type] => utility [patent_app_number] => 14/181931 [patent_app_country] => US [patent_app_date] => 2014-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 37 [patent_no_of_words] => 34194 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14181931 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9597917 [patent_doc_number] => 20140194598 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-10 [patent_title] => 'B7-RELATED NUCLEIC ACIDS AND POLYPEPTIDES USEFUL FOR IMMUNOMODULATION' [patent_app_type] => utility [patent_app_number] => 14/178360 [patent_app_country] => US [patent_app_date] => 2014-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 39 [patent_no_of_words] => 43640 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14178360 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9517769 [patent_doc_number] => 20140154260 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-06-05 [patent_title] => 'B-7 RELATED NUCLEIC ACIDS AND POLYPEPTIDES USEFUL FOR IMMUNOMODULATION' [patent_app_type] => utility [patent_app_number] => 14/177641 [patent_app_country] => US [patent_app_date] => 2014-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 48 [patent_figures_cnt] => 48 [patent_no_of_words] => 76357 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14177641 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9490618 [patent_doc_number] => 20140141024 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-05-22 [patent_title] => 'COMBINATION OF ANTI-CTLA4 ANTIBODY WITH DIVERSE THERAPEUTIC REGIMENS FOR THE SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES' [patent_app_type] => utility [patent_app_number] => 14/168465 [patent_app_country] => US [patent_app_date] => 2014-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 20610 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14168465 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12172087 [patent_doc_number] => 09890215 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-02-13 [patent_title] => 'Vista modulators for diagnosis and treatment of cancer' [patent_app_type] => utility [patent_app_number] => 14/158531 [patent_app_country] => US [patent_app_date] => 2014-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 67 [patent_figures_cnt] => 92 [patent_no_of_words] => 108110 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14158531 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11229868 [patent_doc_number] => 09457080 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-10-04 [patent_title] => 'Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway' [patent_app_type] => utility [patent_app_number] => 14/144304 [patent_app_country] => US [patent_app_date] => 2013-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 30 [patent_no_of_words] => 21958 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14144304 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11763038 [patent_doc_number] => 09371397 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-06-21 [patent_title] => 'CTLA4-Ig immunoadhesins' [patent_app_type] => utility [patent_app_number] => 14/142705 [patent_app_country] => US [patent_app_date] => 2013-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 16 [patent_no_of_words] => 27704 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14142705 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10938864 [patent_doc_number] => 20140341886 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-11-20 [patent_title] => 'TREATMENT WITH ANTI ErbB2 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/141232 [patent_app_country] => US [patent_app_date] => 2013-12-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 17507 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14141232 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10620610 [patent_doc_number] => 09339538 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-05-17 [patent_title] => 'Bystander immune suppression as a predictor for response to a vaccine' [patent_app_type] => utility [patent_app_number] => 14/098679 [patent_app_country] => US [patent_app_date] => 2013-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 10 [patent_no_of_words] => 7823 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14098679 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9568666 [patent_doc_number] => 20140186380 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-03 [patent_title] => 'IMMUNOTHERAPY WITH BINDING AGENTS' [patent_app_type] => utility [patent_app_number] => 14/096510 [patent_app_country] => US [patent_app_date] => 2013-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 35303 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14096510 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10566328 [patent_doc_number] => 09289480 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-03-22 [patent_title] => 'Method for enhancing immune response in the treatment of infectious and malignant diseases' [patent_app_type] => utility [patent_app_number] => 14/079088 [patent_app_country] => US [patent_app_date] => 2013-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 36 [patent_no_of_words] => 7705 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14079088 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9496738 [patent_doc_number] => 08735553 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2014-05-27 [patent_title] => 'Anti-PD1 antibodies and their use as therapeutics and diagnostics' [patent_app_type] => utility [patent_app_number] => 14/076214 [patent_app_country] => US [patent_app_date] => 2013-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 11 [patent_no_of_words] => 18098 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14076214 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9369819 [patent_doc_number] => 20140079692 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-03-20 [patent_title] => 'DOSAGES FOR TREATMENT WITH ANTI-EGFR ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/073659 [patent_app_country] => US [patent_app_date] => 2013-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 26030 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14073659 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9656258 [patent_doc_number] => 20140227262 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-08-14 [patent_title] => 'PD-1 Antagonists and Methods for Treating Infectious Disease' [patent_app_type] => utility [patent_app_number] => 14/069680 [patent_app_country] => US [patent_app_date] => 2013-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 26161 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14069680 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11762274 [patent_doc_number] => 09370565 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-06-21 [patent_title] => 'Dendritic cell co-stimulatory molecules' [patent_app_type] => utility [patent_app_number] => 14/068966 [patent_app_country] => US [patent_app_date] => 2013-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 9 [patent_no_of_words] => 30129 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14068966 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9293916 [patent_doc_number] => 20140037551 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-02-06 [patent_title] => 'ANTIBODIES TO HUMAN B7X FOR TREATMENT OF METASTATIC CANCER' [patent_app_type] => utility [patent_app_number] => 14/050512 [patent_app_country] => US [patent_app_date] => 2013-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 9366 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14050512 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9449452 [patent_doc_number] => 20140120622 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-05-01 [patent_title] => 'T CELL MODIFYING COMPOUNDS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/051244 [patent_app_country] => US [patent_app_date] => 2013-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 25628 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14051244 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10628736 [patent_doc_number] => 09346882 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-05-24 [patent_title] => 'Fully human antibodies to BTLA' [patent_app_type] => utility [patent_app_number] => 14/031319 [patent_app_country] => US [patent_app_date] => 2013-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 38 [patent_no_of_words] => 37580 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14031319 [rel_patent_id] =>[rel_patent_doc_number] =>)